Healthcare

The company said key technical, procedural and operational steps for Stabl-Im are progressing toward a planned Phase 1 clinical evaluation. A clinical feasibility and plasma enrichment study protocol has been advanced, establishing a framework for an initial healthy volunteer study.

Molecular Partners AG (NASDAQ:MOLN), the Swiss clinical-stage biotech developing DARPin miniprotein therapeutics, used its third-quarter 2026 update to formalize what has been an evolving strategy: the company is narrowing its entire focus to radiopharmaceuticals and is restructuring its organization to match. The announcement pairs …

Novocure (NASDAQ:NVCR), a global oncology company working to extend survival in some of the most aggressive cancers through its Tumor Treating Fields (TTFields) therapy, reported net revenues of $193.4 million for the third quarter ended September 30, 2026. This represents a 16% increase from …

Omnicell, Inc. (NASDAQ:OMCL), a healthcare technology company focused on advancing autonomous medication management, reported total revenues of $308 million for the third quarter ended September 30, 2026. This was down $3 million, or 1%, from the third quarter of 2025, but came in above …

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company that acquired Vidya Therapeutics in June 2026, provided a corporate and pipeline progress update covering three developments: clearance of an investigational new drug application from the US Food and Drug Administration for its lead asset VT-7208 …

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on treatments for gastrointestinal diseases, reported net revenues of $84.7 million for the third quarter ended September 30, 2026. This represents a 71% increase from $49.5 million in Q3 2025 and a 14% sequential increase from …

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported consolidated global net product revenues of $1.292 billion for the third quarter ended September 30, 2026, a 52% increase compared with the same period in 2025. The Cambridge, Massachusetts-based RNAi therapeutics company attributed the growth primarily to its TTR …